Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5917877 | 0.84 | HPGD (0.66) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL7357430 | 0.83 | HPGD (0.64) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL6089975 | 0.83 | APEX1 (0.61) | HPGDPOLBALDH1A1MAPTLMNA | |
| SCHEMBL23768982 | 0.80 | HPGD (0.63) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL4050924 | 0.80 | HPGD (0.60) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL3218371 | 0.79 | VCAM1 (0.58) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL21291391 | 0.78 | HPGD (0.61) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL5734347 | 0.78 | VCAM1 (0.68) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL17080196 | 0.78 | HPGD (0.50) | HPGDVCAM1POLBALDH1A1MAPT | |
| SCHEMBL14476018 | 0.77 | HPGD (0.67) | HPGDVCAM1POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022172037-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2022-08-18 | — | — | WO | disclosed |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| CN-1742007-A | Indole-derivative modulators of steroid hormone nuclear receptors | LILLY CO ELI (US) | 2006-03-01 | — | — | CN | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | HPGD 148/4885VCAM1 3379/4885POLB 563/4885 |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | HPGD 281/4885VCAM1 2697/4885POLB 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.